Evaluating HIV drug resistance in the middle East and North Africa and its associated factors: a systematic review DOI Creative Commons
Nastaran Khodadad,

Ava Hashempour,

Mohamad Matin Karbalaei Ali Nazar

et al.

Virology Journal, Journal Year: 2025, Volume and Issue: 22(1)

Published: April 22, 2025

One of the obstacles to achieving successful treatment HIV infections is development and spread mutations linked resistance. Thus, it important monitor prevalence occurrence drug resistance in consistently. This study aimed investigate how affects effectiveness ART. systematic review focused on surveying ART both treatment-naïve treatment-experienced PWH from 2004 2024. Out 101 potential publications, 41 studies were included this review. ART-experienced MENA countries commonly receive a regimen consisting two NRTI drugs combination with one NNRTI drug. The most frequent found NRTIs (M184V, D67N, V75M, M41L, T69N), NNRTIs (K103N, K101E, V106A, G190S), PIs (M36I H69K). groups Israel Iran presented highest rates resistance, reaching 52.78% 43.03%, respectively, whereas ART-naïve group Turkey rate 53.57%. prevalent HIV-1 subtypes region B, CRF35-AD, CRF01-AE, A1, CR02-AG, C, D. A high frequency mutations, such as M184V K103N/S, was observed A, C subtypes. first report provide deep insight into patterns among PWH. results revealed significant RTIs, PIs, INSTIs groups. finding highlights importance prescribing INTIs native RTIs and/or increase chance response well regular monitoring countries. also involves identifying key factors contributing including inadequate adherence lack adequate systems prevent failure. Since an economic challenge, poor medication insufficient may hinder infection control; therefore, control strategies viruses spreading other Not applicable.

Language: Английский

Evaluating HIV drug resistance in the middle East and North Africa and its associated factors: a systematic review DOI Creative Commons
Nastaran Khodadad,

Ava Hashempour,

Mohamad Matin Karbalaei Ali Nazar

et al.

Virology Journal, Journal Year: 2025, Volume and Issue: 22(1)

Published: April 22, 2025

One of the obstacles to achieving successful treatment HIV infections is development and spread mutations linked resistance. Thus, it important monitor prevalence occurrence drug resistance in consistently. This study aimed investigate how affects effectiveness ART. systematic review focused on surveying ART both treatment-naïve treatment-experienced PWH from 2004 2024. Out 101 potential publications, 41 studies were included this review. ART-experienced MENA countries commonly receive a regimen consisting two NRTI drugs combination with one NNRTI drug. The most frequent found NRTIs (M184V, D67N, V75M, M41L, T69N), NNRTIs (K103N, K101E, V106A, G190S), PIs (M36I H69K). groups Israel Iran presented highest rates resistance, reaching 52.78% 43.03%, respectively, whereas ART-naïve group Turkey rate 53.57%. prevalent HIV-1 subtypes region B, CRF35-AD, CRF01-AE, A1, CR02-AG, C, D. A high frequency mutations, such as M184V K103N/S, was observed A, C subtypes. first report provide deep insight into patterns among PWH. results revealed significant RTIs, PIs, INSTIs groups. finding highlights importance prescribing INTIs native RTIs and/or increase chance response well regular monitoring countries. also involves identifying key factors contributing including inadequate adherence lack adequate systems prevent failure. Since an economic challenge, poor medication insufficient may hinder infection control; therefore, control strategies viruses spreading other Not applicable.

Language: Английский

Citations

0